UK Biotech Monument Uses Repurposed Drugs To Target CNS Conditions

Initial Programs In Cognitive Impairment In Schizophrenia, Post-Operative Cognitive Decline

08 Sep 2021

• By Sten Stovall

Emerging Company Profile: Monument Therapeutics’ novel approach to CNS drug development focuses on repurposing existing drugs with the aid of digital biomarkers.

Spinout has access to vast library of validated CNS biomarkers created by its parent • Source: Alamy

Recently spun out from UK-based Cambridge Cognition Holdings plc with 15-months’ worth of working seed capital, CNS-focused Monument Therapeutics is now working to put two repurposed and reformulated compounds into the clinic next year, one to treat cognitive impairment in schizophrenia and another for post-operative cognitive dysfunction, or POCD, a condition arising from major surgery.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Zai’s R&D Head Touts ‘Beauty’ Of Novel Internal Assets

01 May 2025

• By Dexter Jie Yan

Two potentially first-in-class molecules signify Zai Lab’s renewed drive for the in-house discovery of drugs that it requires “to be innovative, differentiated and to have the potential to make a big difference for patients,” its global R&D head tells Scrip.